Gastrointestinale neuroendokrine Tumoren – Update 2024
Lahner H, Pavel ME (2024)
Publication Type: Journal article
Publication year: 2024
Journal
DOI: 10.1007/s00108-024-01734-y
Abstract
Gastrointestinal neuroendocrine tumours (NETs) are rare and clinically heterogeneous. From a diagnostic perspective, well-differentiated tumours must be distinguished from poorly differentiated neuroendocrine carcinomas. The disease may be associated with autonomous hormone secretion by the tumour, and the resulting syndromes are often associated with reduced survival. Somatostatin analogues form the backbone of antiproliferative and antisecretory treatment alongside local ablative procedures. In pancreatic NET, prospective studies confirm the value of specific chemotherapy, particularly in terms of higher remission rates. New tyrosine kinase inhibitors are an option for patients that have failed to respond to standard treatments. Inhibition of HIF2-alpha is an emerging effective treatment option for patients with von Hippel-Lindau-syndrome associated tumours, e.g. pancreatic NET. Radioligand therapy is an established second-line option for advanced NET of the small intestine, and recent study results support its use in pancreatic NET in earlier-line treatment. Due to the complexity of the disease, management of NET patients should be performed in close collaboration with a specialized multidisciplinary team.
Authors with CRIS profile
Involved external institutions
Germany (DE)How to cite
APA:
Lahner, H., & Pavel, M.E. (2024). Gastrointestinale neuroendokrine Tumoren – Update 2024. Innere Medizin. https://doi.org/10.1007/s00108-024-01734-y
MLA:
Lahner, Harald, and Marianne Ellen Pavel. "Gastrointestinale neuroendokrine Tumoren – Update 2024." Innere Medizin (2024).
BibTeX: Download